IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3β

Journal of Immunology

Volumn 192, Issue 8, 2014, Pages 3969-3980

  Fichtner Feigl, Stefan ^a,b,c   Kesselring, Rebecca ^a   Martin, Maria ^a   Obermeier, Florian ^a   Ruemmele, Petra ^a   Kitani, Atsushi ^b   Brunner, Stefan M ^a   Haimerl, Michael ^a   Geissler, Edward K ^a   Strober, Warren ^b   Schlitt, Hans J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Regensburg Center of Interventional Immunology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CHRONIC DISEASE; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRINITROBENZENESULFONIC ACID;

EID: 84898640742     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301072     Document Type: Article

References (41)

1. Beck, P. L., and D. K. Podolsky. 1999. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 44-60.
2. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533.
3. Fiocchi, C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
4. Harper, P. H., V. W. Fazio, I. C. Lavery, D. G. Jagelman, F. L. Weakley, R. G. Farmer, and K. A. Easley. 1987. The long-term outcome in Crohn's disease. Dis. Colon Rectum 30: 174-179.
5. Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
6. Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
7. Fichtner-Feigl, S., I. J. Fuss, J. C. Preiss, W. Strober, and A. Kitani. 2005. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J. Clin. Invest. 115: 3057-3071.
8. Fichtner-Feigl, S., I. J. Fuss, C. A. Young, T. Watanabe, E. K. Geissler, H. J. Schlitt, A. Kitani, and W. Strober. 2007. Induction of IL-13 triggers TGFbeta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis. J. Immunol. 178: 5859-5870.
9. Lawrance, I. C., F. Wu, A. Z. Leite, J. Willis, G. A. West, C. Fiocchi, and S. Chakravarti. 2003. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 125: 1750-1761.
10. Hu, X., J. Chen, L. Wang, and L. B. Ivashkiv. 2007. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J. Leukoc. Biol. 82: 237-243.
11. Hu, X., P. K. Paik, J. Chen, A. Yarilina, L. Kockeritz, T. T. Lu, J. R. Woodgett, and L. B. Ivashkiv. 2006. IFN-γamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24: 563-574.
12. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784.
13. Woodgett, J. R., and P. S. Ohashi. 2005. GSK3: an in-Toll-erant protein kinasë Nat. Immunol. 6: 751-752.
14. Fichtner-Feigl, S., W. Strober, K. Kawakami, R. K. Puri, and A. Kitani. 2006. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGFbeta1 production and fibrosis. Nat. Med. 12: 99-106.
15. Fichtner-Feigl, S., M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H. J. Schlitt, J. A. Berzofsky, and W. Strober. 2008. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 68: 3467-3475.
16. Shimamura, M., R. Morishita, M. Endoh, K. Oshima, M. Aoki, S. Waguri, Y. Uchiyama, and Y. Kaneda. 2003. HVJ-envelope vector for gene transfer into central nervous system. Biochem. Biophys. Res. Commun. 300: 464-471.
17. Boirivant, M., A. Amendola, A. Butera, M. Sanchez, L. Xu, M. Marinaro, A. Kitani, C. Di Giacinto, W. Strober, and I. J. Fuss. 2008. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis. Gastroenterology 135: 1612-1623.e5.
18. Boirivant, M., I. J. Fuss, A. Chu, and W. Strober. 1998. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188: 1929-1939.
19. Fuss, I. J., T. Marth, M. F. Neurath, G. R. Pearlstein, A. Jain, and W. Strober. 1999. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117: 1078-1088.
20. Fichtner-Feigl, S., C. A. Young, A. Kitani, E. K. Geissler, H. J. Schlitt, and W. Strober. 2008. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 135: 2003-2013, 2013.e1-7.
21. Cohen, P., and S. Frame. 2001. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2: 769-776.
22. Neurath, M., I. Fuss, and W. Strober. 2000. TNBS-colitis. Int. Rev. Immunol. 19: 51-62.
23. Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stüber, andW. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-1290.
24. Neurath, M. F., S. Pettersson, K. H. Meyer zum Büschenfelde, and W. Strober. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2: 998-1004.
25. Hazeki, K., K. Nigorikawa, and O. Hazeki. 2007. Role of phosphoinositide 3-kinase in innate immunity. Biol. Pharm. Bull. 30: 1617-1623.
26. Thornton, T. M., G. Pedraza-Alva, B. Deng, C. D. Wood, A. Aronshtam, J. L. Clements, G. Sabio, R. J. Davis, D. E. Matthews, B. Doble, and M. Rincon. 2008. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320: 667-670.
27. Ip, W. K., C. K. Wong, and C. W. Lam. 2006. Interleukin (IL)-4 and IL-13 upregulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clin. Exp. Immunol. 145: 162-172.
28. Wang, H., J. Brown, and M. Martin. 2011. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53: 130-140.
29. Bain, J., L. Plater, M. Elliott, N. Shpiro, C. J. Hastie, H. McLauchlan, I. Klevernic, J. S. Arthur, D. R. Alessi, and P. Cohen. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408: 297-315.
30. Martinez, A., A. Castro, I. Dorronsoro, and M. Alonso. 2002. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22: 373-384.
31. Wilson, M. S., T. R. Ramalingam, A. Rivollier, K. Shenderov, M. M. Mentink-Kane, S. K. Madala, A. W. Cheever, D. Artis, B. L. Kelsall, and T. A. Wynn. 2011. Colitis and intestinal inflammation in IL10-/-mice results from IL-13Ra2-mediated attenuation of IL-13 activity. Gastroenterology 140: 254-264.
32. Frame, S., and P. Cohen. 2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359: 1-16.
33. Jope, R. S., and G. V. Johnson. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29: 95-102.
34. Carter, N. A., E. C. Rosser, and C. Mauri. 2012. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14: R32.
35. Davidson, N. J., M. M. Fort, W. Müller, M. W. Leach, and D. M. Rennick. 2000. Chronic colitis in IL-10-/-mice: insufficient counter regulation of a Th1 response. Int. Rev. Immunol. 19: 91-121.
36. Yoshida, H., H. Jono, H. Kai, and J. D. Li. 2005. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J. Biol. Chem. 280: 41111-41121.
37. Lim, J. H., H. Jono, K. Komatsu, C. H. Woo, J. Lee, M. Miyata, T. Matsuno, X. Xu, Y. Huang, and W. Zhang, et al. CYLD negatively regulates transforming growth factor-b-signalling via deubiquitinating Akt. Nat. Commun. 3: 771.
38. Jang, Y. S., H. A. Kim, S. R. Park, M. R. Lee, J. B. Park, and P. H. Kim. 2009. IL-4 stimulates mouse macrophages to express APRIL through p38MAPK and two different downstream molecules, CREB and Stat6. Cytokine 47: 43-47.
39. Hall, B. M., N. D. Verma, G. T. Tran, and S. J. Hodgkinson. 2011. Distinct regulatory CD4+ T cell subsets; differences between naïve and antigen specific T regulatory cells. Curr. Opin. Immunol. 23: 641-647.
40. Mantel, P. Y., and C. B. Schmidt-Weber. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol. Biol. 677: 303-338.
41. Van Assche, G., K. Geboes, and P. Rutgeerts. 2004. Medical therapy for Crohn's disease strictures. Inflamm. Bowel Dis. 10: 55-60.